In agreement with experimental results obtained by inducing mutations in the MCF10A pre-cancer model, we demonstrated that clones carrying concomitant mutations in the well-known tumor suppressor genes p53 and PTEN, together with the activation of the known cancer driver EGFR, had a growth advantage with respect to clones carrying single mutations or combinations of any two mutations. This evidence concerns the gene TP53 and cancer.